Dent Neurologic Institute

The trials here

What the 35 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease11 trials
• Obesity7 trials
• Migraine5 trials
• Multiple sclerosis5 trials
• Type 2 diabetes4 trials
• Epilepsy2 trials
• ALS (motor neurone disease)1 trial
• Bipolar disorder1 trial
• Myasthenia gravis1 trial
• Parkinson disease1 trial

Phase

• Phase 216 trials
• Phase 310 trials
• Phase 2/33 trials
• Phase 11 trial
• Phase 1/21 trial

Status

• Active, not recruiting12 trials
• Completed10 trials
• Terminated6 trials
• Recruiting5 trials
• Not yet recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• Eli Lilly and Company10 trials
• AEON Biopharma, Inc.2 trials
• Biogen2 trials
• Cassava Sciences, Inc.2 trials
• ACADIA Pharmaceuticals Inc.1 trial
• and 18 more

Running trials

• Not yet recruiting

  A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

  NCT07890376· Phase 2· Eli Lilly and Company· Source

  Contact: Laszlo Mechtler (principal investigator)

• Recruiting

  A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  NCT07589608· Phase 2· Eli Lilly and Company· Source

  Contact: Laszlo Mechtler (principal investigator)

• Recruiting

  Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems

  NCT06959277· RxFunction Inc.· Source

  Contact: Clinical Research Coordinator

• Recruiting

  Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients

  NCT07051629· Phase 1· Suninflam Inc· Source

  Contact: Jacara Washington

• Active, not recruiting

  A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

  NCT06709014· Phase 3· Annovis Bio Inc.· Source

• Recruiting

  RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

  NCT06798896· Phase 2· Supernus Pharmaceuticals, Inc.· Source

  Contact: Supernus Clinical Trials

• Active, not recruiting

  A PIVOTAL STUDY EVALUATING SAFETY AND EFFICACY OF THE SHIRATRONICS MIGRAINE THERAPY SYSTEM

  NCT06167655· ShiraTronics· Source

• Active, not recruiting

  Serum Neurofilament Light in Multiple Sclerosis

  NCT06282081· Dent Neuroscience Research Center· Source

• Active, not recruiting

  A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

  NCT06223360· Phase 2· Weill Medical College of Cornell University· Source

• Recruiting

  A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  NCT06143956· Phase 2· Eli Lilly and Company· Source

  Contact: Laszlo Mechtler (principal investigator)

• Active, not recruiting

  Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

  NCT05397639· Phase 3· Suven Life Sciences Limited· Source

• Active, not recruiting

  Clinical Trial on Agitation in Alzheimer's Dementia

  NCT05543681· Phase 2· IGC Pharma, LLC· Source

• Active, not recruiting

  A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

  NCT05399888· Phase 2· Biogen· Source

• Active, not recruiting

  A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

  NCT04616326· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  HEALEY ALS Platform Trial - Master Protocol

  NCT04297683· Phase 2/3· Merit E. Cudkowicz, MD· Source

• Active, not recruiting

  Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

  NCT04146051· Phase 2· Cartesian Therapeutics· Source

• Active, not recruiting

  A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

  NCT03432286· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity3 recruiting
• Type 2 diabetes3 recruiting
• Epilepsy2 recruiting

Closed trials

• Completed

  A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06683508· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  NCT06603571· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06230523· Phase 2· Eli Lilly and Company· Source

• Completed

  A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

  NCT06124807· Phase 2· Eli Lilly and Company· Source

• Recruiting

  ACP-204 in Adults With Alzheimer's Disease Psychosis

  NCT06159673· Phase 2/3· ACADIA Pharmaceuticals Inc.· Source

  Contact: Christine Murphy

• Completed

  Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis

  NCT06083753· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease

  NCT05642442· Phase 2· Jazz Pharmaceuticals· Source

• Terminated

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· Phase 3· Cassava Sciences, Inc.· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Biogen· Source

• Completed

  NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

  NCT03395392· Phase 2/3· NeuroRx, Inc.· Source

• Completed

  Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT04994483· Phase 3· Cassava Sciences, Inc.· Source

• Terminated

  Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention

  NCT05016661· Phase 2· AEON Biopharma, Inc.· Source

• Completed

  Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

  NCT04845178· Phase 2· AEON Biopharma, Inc.· Source

• Terminated

  Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

  NCT04140305· Phase 3· Celgene· Source

• Completed

  A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)

  NCT03933202· EMD Serono Research & Development Institute, Inc.· Source

• Terminated

  Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

  NCT03283826· Phase 1/2· Atara Biotherapeutics· Source

• Terminated

  Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

  NCT02446132· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source